This study from one clinic examined how well sotatercept worked in real-world patients with pulmonary arterial hypertension (PAH) who also had other heart or lung conditions, such as coronary artery disease, high blood pressure, lung scarring, or COPD. After six months of treatment, patients generally needed less oxygen, walked farther in six-minute walk tests, and showed improvements in their overall risk scores. Most side effects, such as nosebleeds or increased red blood cell levels, were...

June 3 is Clean Air Day in Canada Air quality in Canada is relatively good, but anyone with pulmonary hypertension (PH) will be aware that air quality affects our health. Air pollution from humans burning fossil fuels for transportation, home heating and cooking, and in industry is significant, but due to climate change, air pollution from dust, pollen, and wildfires is also increasing. For people with pulmonary hypertension, air quality is especially important. On World Pulmonary...

This study looked at a French support program designed to help people with pulmonary arterial hypertension (PAH) start and adjust their dose of selexipag. Nurses called patients three days after patients started treatment or changed doses to monitor side effects and provide guidance. Most patients were able to reach their best individual dose within about 11 weeks, and most side effects were mild or manageable. Both patients and healthcare providers reported very high satisfaction with the...